Aramchol free acid + Placebo
Phase 3Active 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nonalcoholic Steatohepatitis (NASH)
Conditions
Nonalcoholic Steatohepatitis (NASH)
Trial Timeline
Sep 23, 2019 → Jun 30, 2027
NCT ID
NCT04104321About Aramchol free acid + Placebo
Aramchol free acid + Placebo is a phase 3 stage product being developed by Galmed Pharmaceuticals for Nonalcoholic Steatohepatitis (NASH). The current trial status is active. This product is registered under clinical trial identifier NCT04104321. Target conditions include Nonalcoholic Steatohepatitis (NASH).
What happened to similar drugs?
0 of 5 similar drugs in Nonalcoholic Steatohepatitis (NASH) were approved
Approved (0) Terminated (3) Active (2)
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04104321 | Phase 3 | Active |
Competing Products
20 competing products in Nonalcoholic Steatohepatitis (NASH)